Karuna Therapeutics, Inc. (KRTX)
Market Cap | 6.37B |
Revenue (ttm) | 10.64M |
Net Income (ttm) | -276.34M |
Shares Out | 34.89M |
EPS (ttm) | -8.74 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 922,451 |
Open | 176.03 |
Previous Close | 176.22 |
Day's Range | 174.40 - 183.34 |
52-Week Range | 92.26 - 278.25 |
Beta | 1.17 |
Analysts | Buy |
Price Target | 288.00 (+57.88%) |
Earnings Date | May 4, 2023 |
About KRTX
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psych... [Read more]
Financial Performance
In 2022, KRTX's revenue was $10.64 million, a decrease of -71.22% compared to the previous year's $36.96 million. Losses were -$276.34 million, 92.2% more than in 2021.
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for KRTX stock is "Buy." The 12-month stock price forecast is $288.0, which is an increase of 57.88% from the latest price.
News

Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc.

Karuna Therapeutics to Present at the Stifel 2023 CNS Days
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a...

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study
Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.

Karuna Therapeutics Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

Why Is Karuna Therapeutics (KRTX) Stock Moving Today?
Karuna Therapeutics (NASDAQ: KRTX) stock is on the move Monday after releasing results from a Phase 3 clinical trial for KarXT. KarXT is a drug in development by the company to treat adults with schi...

Karuna's stock is up after schizophrenia drugs meets primary endpoint in clinical trial
Shares of Karuna Therapeutics Inc. KRTX, +1.21% rallied about 14% in premarket trading on Monday after the company said its experimental treatment for adults with schizophrenia met the primary endpoin...

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4
Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.

Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates
Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio's Investigational TRPC4/5 Product Candidates
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX) and GFB (ABC), LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement...

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric...

Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric...

Moore Kuehn, PLLC Encourages Investors of Karuna Therapeutics, Inc. to Contact Law Firm
NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ: ...

Why Karuna Therapeutics Shares Are Trading Sharply Lower - Karuna Therapeutics (NASDAQ:KRTX)
Karuna Therapeutics Inc KRTX shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition.

Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric...

Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss
Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.

Karuna Therapeutics, Inc. (KRTX) Reports Q3 Loss, Misses Revenue Estimates
Karuna Therapeutics, Inc. (KRTX) delivered earnings and revenue surprises of -19.60% and 99.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
PARAMUS, N.J.--(BUSINESS WIRE)--PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage ...

Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...